Skip to main content
Premium Trial:

Request an Annual Quote

Genentech, Illumina, Agilent Technologies, TeleChem International, XGene, Affymetrix

Premium

Genentech of South San Francisco, Calif., has received US Patent No. 6,914,130, "Compositions and methods for the diagnosis and treatment of tumor." The patent identifies various cellular polypeptides, as well as their encoding nucleic acids or fragments, which are expressed to a greater degree on the surface of one or more types of cancer cell as compared to on the surface of one or more types of normal non-cancer cells. Such polypeptides are referred to as tumor-associated antigenic target polypeptides, or "TAT" polypeptides, by the inventors and are expected to serve as targets for cancer therapy and diagnosis in mammals, according to the patent.


Illumina of San Diego has received US Patent No. 6,913,884, "Compositions and methods for repetitive use of genomic DNA." The patent describes a substrate comprising immobilized target nucleic acids which, in turn, comprise genomic DNA and an attachment moiety for attaching the genomic DNA to the substrate, such that the attachment moiety is capable of withstanding multiple analyses of the genomic DNA. A method is subsequently provided for performing a first analysis of the target sequences where the immobilized genomic DNA is not consumed, followed by a second analysis of the immobilized genomic DNA target sequences. Preferably, the first and second analyses are genotyping analyses that can also include amplification reactions, the patent states.


Agilent Technologies of Palo Alto, Calif., has received US Patent No. 6,913,200, "Scanning parameterization for biopolymeric array scanner." The patent describes methods for programming an array scanner to scan a plurality of biopolymer arrays. In the provided methods, individual scanning parameters for at least two different arrays of the plurality of arrays to be scanned are selected and fed into the array scanner prior to scanning the plurality of arrays. The programmed scanner then scans the plurality of arrays according to the pre-selected scanning parameters. The patent also provides scanners programmed according to the described methods, as well as computer programming that provides for programming of scanners according to the subject methods. The subject methods and compositions can be used in both genomics and proteomics applications, the patent states.


TeleChem International of Sunnyvale, Calif., has received US Patent No. 6,913,879, "Microarray method of genotyping multiple samples at multiple loci." The patent provides a method for genotyping multiple samples at multiple genetic loci in a single assay. According to the method, genomic segments from multiple samples are amplified using PCR primers, where each genomic segment contains a DNA marker of interest. The genomic segments are formed into a microarray on a surface where the material at each location of the surface corresponds essentially to a single genomic segment from a single sample. The microarray is hybridized with a mixture of synthetic oligonucleotides that are complementary to the genomic segments on the micorarray, the patent states. Genotyping information for the multiple samples is then derived simultaneously by reading the microarray signals. The method can be used for disease diagnostics or to screen for alleles from any plant or animal species.


XGene of Burlingame, Calif., has received US Patent No. 6,913,880, "Method for determining transcription factor activity and its technical uses." The patent describes assays for determining which transcription factors are actively catalyzing the transcription of a gene in any cell type, or in any cell in response to any drug or treatment. The patent claims that the group of transcription factors has a predictable molecular biological activity in addition to transcription activation, namely site-specific DNA strand cleavage.


Affymetrix of Santa Clara, Calif., has received US Patent No. 6,913,882, "Methods of screening for B cell activity modulators." The patent described a method for the identification of all genes, whether known or novel, which are differentially expressed within and among B cells, making possible the characterization of their temporal regulation and function in the B cell response and/or in B cell mediated disorders. Expression profiles, nucleic acids and proteins are provided for differing states of B cells, including resting, naive, activated, tolerant and immunosuppressed B cells in the patent. The patent claims the invention makes possible the identification and characterization of targets useful in prognosis, diagnosis, monitoring, rational drug design, and/or therapeutic intervention of immune system disorders.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.